About Ocera Therapeutics
Ocera Therapeutics is focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases. The company's portfolio consists of OCR-002 and AST-120. OCR-002 is an ammonia scavenger in development for the treatment and prevention of hyperammonemia and resultant Acute Hepatic Encephalopathy (AHE) in patients with liver cirrhosis and Acute Liver Failure (ALF). OCR-002 is developed in both oral and IV formulations. AST-120 is a microspherical carbon adsorbent with selective adsorption profile for a variety of unwanted substances in the digestive tract. These substances may be responsible for a number of conditions, including Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), and pouchitis. They include ammonia, indoles (serotonin, octopamine), histamine, secondary bile acids, advanced glycation endproducts (AGE), and certain bacterial toxins.
Missing: Ocera Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Ocera Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Ocera Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ocera Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Ocera Therapeutics Patents
Ocera Therapeutics has filed 31 patents.
Hepatology, Diseases of liver, Cytokines, Histone deacetylase inhibitors, Inflammations
Hepatology, Diseases of liver, Cytokines, Histone deacetylase inhibitors, Inflammations
Latest Ocera Therapeutics News
Nov 6, 2018
Printed From BioPortfolio.com Ocera Therapeutics Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350 18:46 EST 5 Nov 2018 | BioPortfolio Reports Ocera Therapeutics Inc Mergers Acquisitions MA, Partnerships Alliances and Investment Report Summary Marketline's Ocera Therapeutics Inc Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ocera Therapeutics Inc since January2007. Synopsis Marketline's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This report includes Ocera Therapeutics Inc's contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed. The profile also includes detailed deal reports for all MA, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Ocera Therapeutics Inc. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed. Scope Provides intelligence on Ocera Therapeutics Inc's MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Ocera Therapeutics Inc and its subsidiaries since 2007. Information about key financial and legal advisors for Ocera Therapeutics Inc's financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. Reasons to buy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Ocera Therapeutics Inc's growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Ocera Therapeutics Frequently Asked Questions (FAQ)
When was Ocera Therapeutics founded?
Ocera Therapeutics was founded in 2005.
Where is Ocera Therapeutics's headquarters?
Ocera Therapeutics's headquarters is located at 555 Twin Dolphin Drive, Redwood City.
What is Ocera Therapeutics's latest funding round?
Ocera Therapeutics's latest funding round is Acq - P2P.
How much did Ocera Therapeutics raise?
Ocera Therapeutics raised a total of $62M.
Who are the investors of Ocera Therapeutics?
Investors of Ocera Therapeutics include Mallinckrodt, Tranzyme Pharma, Thomas McNerney & Partners, Domain Associates, Sofinnova Ventures and 10 more.
Who are Ocera Therapeutics's competitors?
Competitors of Ocera Therapeutics include Portola Pharmaceuticals, Aduro BioTech, Probiodrug, REGiMMUNE, VLST Corporation, Neurotech, BrainCells, Sonexa Therapeutics, Aerovance, TargeGen and 12 more.
Compare Ocera Therapeutics to Competitors
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
nnBio3 Research s.r.l. is a private biopharmaceutical company based in Milan, Italy, with a USA subsidiary, Bio3 Research Inc., based in Hayward/CA. Bio3 Research develops new compounds up to IND stage with potential in cardiovascular field. The company is focused in the area of cardiovascular disorders related to HMGB1 (High Mobility Group Box 1) over-expression.
BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.
Biopharmaceutical company developing enabling technology platforms and enhanced natural therapeutics for certain infectious diseases, cancers and CNS disorders. Ehanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.